APYXHealthcare · Medical Devices

APYX Stock Forecast: Apyx Medical Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$2.90

+0.35% on the day

The 5 Wall Street analysts covering Apyx Medical Corp. hold a median 12-month price target of $6 — +106.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 11 Sept 2026 — in the upper half.

Market cap

$121.7M

Ticker Nerd rank

63 / 100

Median analyst target

$6.00

Analysts covering

Revenue$13.9M+22.1% y/y

Operating income−$1.8M

Net income−$3.1M

Free cash flow−$3.6M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−5.2%

−4.0%

YTD

−17.1%

+45.0%

From 52W high

−40.3%

From 52W low

+45.0%

$2.00

$4.86

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

APYX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Apyx Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026

63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth

Size

Quality

Momentum

Revisions

Value

Volatility

Issuance

Accruals

Growth (85): Sales and profits are climbing, and climbing faster than before.

Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

APYX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APYX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts

5 Buy0 Hold0 Sell

Low $6.00Median $6.00High $8.00

The green dot is the last close — the median target sits +106.9% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
13 July 2026	HC Wainwright & Co.	Initiates	Buy	$7.00
11 Mar 2026	BTIG	Upgrade	Buy	—
11 Mar 2026	Craig-Hallum	Maintains	Buy	—
16 Dec 2025	Roth Capital	Initiates	Buy	—
12 Nov 2025	Citizens	Upgrade	Market Outperform	—
17 Oct 2024	BTIG	Initiates	Neutral	—
16 Sept 2024	JMP Securities	Reiterates	Market Perform	—
10 Nov 2023	Stephens & Co.	Maintains	Overweight	—
11 Aug 2023	Piper Sandler	Maintains	Overweight	—
14 July 2023	Stephens & Co.	Initiates	Overweight	—
15 June 2023	Lake Street	Maintains	Buy	—
24 May 2023	JMP Securities	Reiterates	Market Perform	—
12 May 2023	Lake Street	Maintains	Buy	—
8 Dec 2022	Lake Street	Assumes	Buy	$5.00
12 Aug 2022	Piper Sandler	Maintains	Overweight	—
19 July 2022	Lake Street	Maintains	Buy	—
20 May 2022	Lake Street	Initiates	Buy	—
13 Aug 2021	JMP Securities	Maintains	Market Outperform	—
12 May 2020	JMP Securities	Maintains	Market Outperform	—
12 Nov 2019	Piper Jaffray	Maintains	Overweight	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. APYX appears on the weeks it earns a place.

Performance

APYX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Apyx Medical Corp. returned +45.0% against +17.5% for the S&P 500, dividends included.

APYX vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APYX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Apyx Medical Corp. (APYX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −10.7×
Price / sales: 2.1×
Price / book: 11.4×
EV / EBITDA: −48.7×

Growth & margins

Revenue growth (YoY): 22.1%
Earnings growth (YoY): 22.1%
Gross margin: 63.9%
Operating margin: −13.0%
Net margin: −14.8%

Returns & dividend

Return on equity: −90.7%
Return on assets: −3.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Apyx Medical Corp. (APYX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Apyx Medical Corp. has a market value of $121.7M and an enterprise value of $134.2M.
Revenue in the twelve months to 30 June 2026: $58.4M. The latest quarter grew 22.1% year on year.
Net income over the same four quarters: −$8.4M, a −14.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.20.
Free cash flow in the twelve months to 30 June 2026: −$11.0M.
Shares outstanding: 42.1M.
Trailing P/E: −10.7×; forward P/E: −11.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Apyx Medical Corp. employs 205 people — $285K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

APYX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
APYXApyx Medical Corp.	$121.7M	63
QTRXQuanterix Corp.	$120.6M	29
MXCTMaxCyte, Inc.	$124.3M	75
OWLTOwlet, Inc.	$136.0M	34
INGNInogen, Inc.	$144.6M	82
MBOTMicrobot Medical, Inc.	$97.4M	15
LNSRLENSAR, Inc.	$90.7M	62

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Apyx Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest APYX news & analysis

Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring

MarketBeat · 12 Aug 2026positive

Apyx Medical is positioning its Renuvion technology and newly launched AYON Body Contouring System to serve growing demand for surgical aesthetic procedures. CEO Charlie Goodwin said this demand has been reshaped by the increasing use of GLP-1 weight-loss drugs.

Why it matters — Apyx watchers would care because the company is framing its aesthetic-device lineup as a beneficiary of the GLP-1 weight-loss trend driving demand for body-contouring procedures.

Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the Q2 2026 earnings call transcript for Apyx Medical Corporation (APYX). The transcript covers the company's second-quarter 2026 earnings discussion with investors.

Why it matters — APYX watchers can review management's own commentary on the company's Q2 2026 results directly from the earnings call.

Apyx Medical (APYX) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 7 Aug 2026negative

Apyx Medical reported a Q2 loss of $0.07 per share, which came in wider than the Zacks Consensus Estimate of a $0.06 loss, though narrower than the $0.09 per-share loss a year earlier. The company beat revenue estimates for the quarter.

Why it matters — For APYX watchers, the quarter shows the company's bottom-line loss improved year over year while still coming in slightly worse than analyst expectations, offering a read on its earnings trajectory.

Apyx Medical Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Apyx Medical reported second-quarter revenue growth of 22% on its quarterly earnings call. The increase was driven by its surgical aesthetics business, boosted by adoption of the AYON Body Contouring System, international generator sales, and domestic demand for single-use handpieces.

Why it matters — APYX watchers would note the 22% revenue growth and the drivers cited for the company's recent performance.

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 6 Aug 2026neutral

Apyx Medical Corporation (NASDAQ:APYX), which markets Renuvion and the AYON Body Contouring System, reported its financial results for the second quarter ended June 30, 2026. The results were announced on August 6, 2026.

Why it matters — APYX watchers will want to track this quarterly financial report as it provides the latest update on the company's performance.

FAQ

Frequently asked questions about APYX stock

What is the APYX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Apyx Medical Corp. have a median 12-month price target of $6, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APYX stock a buy right now?

Of the 5 analysts covering Apyx Medical Corp., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apyx Medical Corp. 63 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APYX?

As at 11 Sept 2026, Apyx Medical Corp. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

Will APYX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +106.9% from the last close, and Ticker Nerd's factor model ranks Apyx Medical Corp. 63 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APYX stock forecast for 2030?

No analyst covering Apyx Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APYX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.

How has APYX stock performed over the past year?

Apyx Medical Corp. returned +45.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Apyx Medical Corp. do?

What is the latest news on APYX?

The most recent item we track (MarketBeat, 12 Aug 2026): "Apyx Medical Sees GLP-1 Boom Fueling Demand for Renuvion, AYON Body Contouring". Apyx Medical is positioning its Renuvion technology and newly launched AYON Body Contouring System to serve growing demand for surgical aesthetic procedures. CEO Charlie Goodwin said this demand has been reshaped by the increasing use of GLP-1 weight-loss drugs.

Company

About Apyx Medical Corp.

Apyx Medical Corporation is a medical technology company that develops, manufactures, and markets advanced energy-based surgical products for cosmetic and general surgical use. The company’s portfolio includes helium plasma technology systems, handheld devices, generators, and related accessories designed to support precise tissue cutting, coagulation, and ablation in open and minimally invasive procedures. Its products are used by physicians, surgery centers, hospitals, and other healthcare providers across surgical aesthetics and broader electrosurgical applications. Apyx Medical Corporation also serves original equipment manufacturing customers with engineered medical devices and components. Headquartered in Clearwater, Florida, Apyx Medical Corporation focuses on tools that combine energy delivery and surgical performance for modern operating environments.

CEO Mr. Charles D. Goodwin II · 205 employees · United States · https://apyxmedical.com